Rapamycin (Sirolimus) Cost in Washington 2026: Prices, Insurance, and Savings

Why one advertised monthly price is misleading

Sirolimus is sold as tablets in multiple strengths and as an oral solution. A prescription can differ in dosage form, strength, number of units, days supplied, manufacturer, and whether substitution is permitted. Any of those differences can change the cash price or the way a pharmacy benefit processes the claim.

A defensible Washington price comparison therefore begins with one exact prescription. Ask each pharmacy to quote the same National Drug Code if possible, or at least the same manufacturer, strength, dosage form, quantity, and days supplied. Confirm whether the number is a cash price, an insurance adjudication, or a discount-program price. Those are different transactions and may not be combinable.

An online coupon is a useful lead, not a guaranteed checkout price. Pharmacy participation, inventory, quantity limits, and discount terms can change. The actual amount due is the quote the dispensing pharmacy returns for the prescription on that day.

What sirolimus is approved to treat

Current U.S. labeling describes sirolimus as an mTOR-inhibitor immunosuppressant used to prevent organ rejection in people age 13 or older receiving kidney transplants and to treat lymphangioleiomyomatosis (LAM). The label describes daily administration and therapeutic drug monitoring for those labeled clinical settings. It does not contain a weekly “longevity protocol.” See the current DailyMed sirolimus prescribing information.

That boundary changes both access and cost. A plan may cover a drug for one diagnosis but require prior authorization, supporting records, or an exception for another. A pharmacy's ability to dispense a valid prescription does not mean an insurer must pay for an off-label use.

How to check Apple Health coverage

Washington's Health Care Authority says its managed-care plans and fee-for-service program use the Apple Health Preferred Drug List. Because preferred status, prior-authorization rules, dosage forms, and effective dates can change, use the current Apple Health Preferred Drug List page rather than relying on an old screenshot or a fixed co-pay claim.

For an actionable answer, search the current list for both sirolimus and Rapamune, then verify:

• whether the listed entry is a tablet or oral solution;
• whether it is preferred or nonpreferred;
• whether prior authorization or another restriction appears;
• whether the document is effective on the fill date; and
• whether the person's managed-care plan has a specific processing instruction.

The Apple Health pharmacy services page explains that drugs on the PDL are generally paid according to the program's current rules. It does not support a universal statement that every sirolimus prescription has a particular co-pay or that off-label longevity use will be covered.

Commercial insurance, Medicare, and cash pay

For commercial or Medicare drug coverage, the relevant evidence is the member's current formulary and a pharmacy claim for the exact prescription. A broad statement that “most Washington plans cover sirolimus at Tier 2” is not reliable: formularies differ by product, employer group, benefit year, indication, and authorization status.

A practical comparison separates three numbers:

For insured fills, ask what the price will be before and after any deductible is met. For cash fills, compare independent, chain, hospital, and mail-order pharmacies using the same prescription details. Do not assume a brand coupon applies to a generic product, an uncovered indication, or government insurance.

Compounded sirolimus is not simply a cheaper generic

FDA-approved sirolimus tablets and oral solution are commercially available. Under federal section 503A, a traditional compounding pharmacy generally may not regularly make products that are essentially copies of commercially available drugs. A patient-specific compounded version may qualify when the prescriber documents that a change produces a significant difference for the identified patient, but “custom dose” or “longevity use” alone should not be presented as automatic permission.

The FDA's compounding questions and answers explains that compounded drugs are not FDA-approved and are not reviewed in advance for safety, effectiveness, or quality. Compounding may be appropriate when a patient's medical need cannot be met by an approved product; it is not evidence that the compounded version is clinically superior or less expensive.

Washington licenses pharmacies by location and ownership. The Department of Health states that an out-of-state pharmacy shipping legend drugs into Washington needs a Washington nonresident-pharmacy license. The state's pharmacy licensing information and provider credential search are more reliable than a clinic's claim that a partner pharmacy is “licensed nationwide.”

What human longevity research actually shows

Animal studies are important for generating hypotheses, but they cannot establish that sirolimus extends human life or determine a human anti-aging dose. The Washington-based dog study sometimes cited in marketing, A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs, tested 24 companion dogs. It did not test human lifespan, Washington pharmacy access, insurance coverage, or price.

One earlier placebo-controlled feasibility trial enrolled only 25 generally healthy adults age 70 to 95. It reported potential adverse effects and changes in several red-blood-cell measures, but its small sample and short duration could not establish an anti-aging effect. See A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.

The 48-week PEARL trial studied intermittent, low-dose rapamycin in generally healthy adults. Its authors reported that treatment was relatively safe in that research setting and described exploratory findings, including sex-specific differences in lean tissue mass and pain. The trial did not demonstrate longer human survival, and its intervention should not be converted into a standard prescription schedule. See Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.

A 2025 review of clinical evidence reached the same core limit: human data have not established rapamycin or related drugs as proven treatments that delay aging in healthy adults. See What is the clinical evidence to support off-label rapamycin therapy in healthy adults?.

That evidence gap is important to a cost calculation. A recurring drug expense is not evidence of benefit, and a package that bundles medication, visits, and laboratory testing should not be described as medically validated simply because it is sold by a longevity clinic.

Safety and monitoring affect total cost

Sirolimus is an immunosuppressant with clinically significant risks and interactions. Current labeling includes warnings about serious infection and malignancy risk, impaired wound healing, elevated lipids, protein in the urine, cytopenias, lung toxicity, and serious hypersensitivity reactions. It is metabolized through CYP3A4 and transported by P-glycoprotein, so strong inhibitors or inducers can materially change exposure. Grapefruit can also affect concentrations.

For the FDA-approved indications, the label recommends sirolimus trough monitoring and ties interpretation to clinical findings and laboratory parameters. There is no validated universal laboratory calendar for healthy people taking it for longevity. A quote that includes only tablets may omit the cost of the evaluation needed to determine whether a prescription is appropriate, medication-interaction review, and any clinically indicated follow-up.

A reproducible Washington cost checklist

1. Confirm whether the request concerns an FDA-approved indication or off-label longevity use.
2. Obtain the exact form, strength, manufacturer preference, quantity, and days supplied.
3. Check the current plan formulary and authorization requirements using the member's benefit, not a statewide generalization.
4. Ask at least two licensed pharmacies to process or quote the identical prescription.
5. Confirm that a quoted discount replaces or works with insurance before comparing totals.
6. If a compounded product is proposed, ask what documented patient-specific need the approved product cannot meet.
7. Verify a Washington pharmacy or nonresident-pharmacy credential before using mail order.
8. Add separate visit and monitoring charges only when they are actually part of the proposed care.

This process produces a current, auditable answer without inventing a statewide average, guaranteed insurance approval, or a low-price access path that may not exist for the prescription in question.